Table 1 Patient characteristics.
From: Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
Total number of patients | 41 |
Male (%) | 23 (56%) |
Age (years) | 73 (69–81) |
Weight (kg) | 87 (74–94) |
Body surface area (m2) | 2.03(1.83–2.11) |
Stage (AJCCv8) | |
IV | 35 (85%) |
III | 6 (15%) |
Progression at 6 months | 7 (17%) |
